Tempus AI Receives FDA Clearance For Tempus ECG-PH For Signs Associated With Pulmonary Hypertension
Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes
Tempus AI got official permission from the FDA to sell a smart computer tool that helps doctors spot signs of a heart disease called pulmonary hypertension. This approval shows the company's technology works and is ready to help real patients, which is a meaningful step forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.